Applied DNA Sciences, Inc.
APDN
$3.75
-$0.34-8.31%
| Weiss Ratings | APDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | APDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | APDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 3.75 | |||
| Price History | APDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -43.69% | |||
| 30-Day Total Return | -49.60% | |||
| 60-Day Total Return | -67.53% | |||
| 90-Day Total Return | -69.81% | |||
| Year to Date Total Return | -69.76% | |||
| 1-Year Total Return | -80.91% | |||
| 2-Year Total Return | -89.47% | |||
| 3-Year Total Return | -97.28% | |||
| 5-Year Total Return | -99.19% | |||
| 52-Week High % Change | -86.56% | |||
| 52-Week Low % Change | 22.85% | |||
| Price | APDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $1.86 | |||
| 52-Week Low Price | $0.31 | |||
| 52-Week Low Price (Date) | Apr 17, 2024 | |||
| 52-Week High Price (Date) | Aug 01, 2023 | |||
| Valuation | APDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 5.83M | |||
| Enterprise Value | 3.48M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.55 | |||
| Earnings Per Share Growth | -23.17% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.52 | |||
| Price/Book (Q) | 1.11 | |||
| Enterprise Value/Revenue (TTM) | 0.22 | |||
| Price | $3.75 | |||
| Enterprise Value/EBITDA (TTM) | -0.16 | |||
| Enterprise Value/EBIT | -0.15 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | APDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 13.67M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | APDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 631 240 8800 | |||
| Address | 50 Health Sciences Drive Stony Brook, NY 11790 | |||
| Website | www.adnas.com | |||
| Country | United States | |||
| Year Founded | 1983 | |||
| Profitability | APDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -150.32% | |||
| Profit Margin | -80.13% | |||
| Management Effectiveness | APDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -55.95% | |||
| Return on Equity | -- | |||
| Income Statement | APDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 9.00M | |||
| Total Revenue (TTM) | 9.00M | |||
| Revenue Per Share | $13.16 | |||
| Gross Profit (TTM) | 3.39M | |||
| EBITDA (TTM) | -12.20M | |||
| EBIT (TTM) | -13.52M | |||
| Net Income (TTM) | -7.21M | |||
| Net Income Avl. to Common (TTM) | -7.21M | |||
| Total Revenue Growth (Q YOY) | -83.07% | |||
| Earnings Growth (Q YOY) | 70.60% | |||
| EPS Diluted (TTM) | -10.99 | |||
| EPS Diluted Growth (Q YOY) | 70.00% | |||
| Balance Sheet | APDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 3.36M | |||
| Cash Per Share (Q) | $4.91 | |||
| Total Current Assets (Q) | 4.59M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 4.13M | |||
| Current Ratio (Q) | 1.774 | |||
| Book Value Per Share (Q) | $0.31 | |||
| Total Assets (Q) | 9.91M | |||
| Total Current Liabilities (Q) | 2.59M | |||
| Total Debt (Q) | 1.12M | |||
| Total Liabilities (Q) | 5.78M | |||
| Total Common Equity (Q) | 4.23M | |||
| Cash Flow | APDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -1.14M | |||
| Cash from Financing (TTM) | -35.10K | |||
| Net Change in Cash (TTM) | -8.77M | |||
| Levered Free Cash Flow (TTM) | -4.62M | |||
| Cash from Operations (TTM) | -7.59M | |||
